Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked conscientiously but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will ever be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire interview which I came away with a poor impression of the business.

Irony of irony, my bad opinion of the company has grown steadily, however, the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and also connected intellectual property from Progenics to CytoDyn, as well as approximately twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and also the first new drug program approval ($five million), and also royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to get a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple therapies and multiple indications, it’s this individual remedy and a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several disease sorts, multiple publications in addition to multiple presentations.

Could all this be smoke and mirrors? That is a question I’ve been asking myself through the very start of the interest of mine in this particular organization. Judging by the multiples of thousands of diverse responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this question.

CytoDyn is a traditional battleground, or even some may say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *